ERBB2 and breast cancer: HER2-targeted monoclonal antibodies (mAbs) such as trastuzumab and/or pertuzumab (used as single or combined agents, with or without chemotherapy) are now the standard treatment for patients with HER2-positive advanced BC, acting to block the corresponding pathway(s) and provide improved overall survival rates [7].